← Leaderboards
Keiran Smalley
H. Lee Moffitt Cancer Ctr & Res Inst
$7,060,803
Attributed
$11,548,052
Total exposure
11
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2011–25$2.5M$1.9M$1.3M$625K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,548,052 · 11
By mechanism
R01$8,742,731 · 5
R21$1,682,698 · 4
P50$1,097,587 · 1
R13$25,036 · 1
Top collaborators
- Jonathan D. Licht9 shared
- James W Harbour5 shared
- Peter Alexander Forsyth2 shared
- Weizhou Zhang2 shared
- Guangrong Zheng2 shared
- Vincent Christopher Luca1 shared
Most similar at H. Lee Moffitt Cancer Ctr & Res Inst
Same institution · by research overlap
- Peter Alexander Forsyth$534,316
- Inna Smalley$1,373,060
Others in their field
Top investigators on “Melanoma Cell”
- David Heimbrook · Leidos Biomedical Research, Inc.$132,779,807
- Larry Arthur$50,900,237
- Meenhard Herlyn · University Of Pennsylvania$37,484,052
- Ze'ev A Ronai · Mount Sinai School Of Medicine Of Cuny$32,114,278
- John H Sampson · Duke University$27,440,880
- Walter C. Willett · Harvard University (Sch Of Public Hlth)$26,930,282
Research focus
Melanoma CellMediatingSignal TransductionSpecimenMelanomaCellsTumorResponseIn VivoPreventPathway InteractionsResistanceBraf GeneEnvironmentDrug ResistanceTargeted TreatmentMeksClinical TrialsCell LineMutantInnovationPhenotypeMutationIn Vitro
Grant awards (31)
Proteolysis targeting chimera against nuclear receptor NR4A1 for melanoma therapy$655,441
R01 · FY2025 · CA
Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis$651,147
R01 · FY2025 · CA · contact PI
Structure-function studies of LAG3 interactions with antibodies and cellular ligands$549,962
R01 · FY2025 · CA
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma$485,968
R01 · FY2025 · CA · contact PI
26th Annual Meeting of the PanAmerican Society for Pigment Cell Research$25,036
R13 · FY2025 · AR · contact PI
Proteolysis targeting chimera against nuclear receptor NR4A1 for melanoma therapy$678,605
R01 · FY2024 · CA
Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis$618,592
R01 · FY2024 · CA · contact PI
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma$463,483
R01 · FY2024 · CA · contact PI
Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis$638,384
R01 · FY2023 · CA · contact PI
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma$478,486
R01 · FY2023 · CA · contact PI
Defining and targeting the epigenetic programs involved in melanoma development$192,997
R21 · FY2023 · CA · contact PI
Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis$638,640
R01 · FY2022 · CA · contact PI
Defining and targeting epigenetic plasticity-driven drug resistance and immune escape in melanoma$498,307
R01 · FY2022 · CA · contact PI
Defining and targeting the epigenetic programs involved in melanoma development$236,321
R21 · FY2022 · CA · contact PI
Targeting the suppressive immune microenvironment in leptomeningeal melanoma metastases$188,644
R21 · FY2022 · CA · contact PI
Characterization and targeting of the epigenetic state underlying uveal melanoma liver metastasis$684,278
R01 · FY2021 · CA · contact PI
Targeting the suppressive immune microenvironment in leptomeningeal melanoma metastases$230,992
R21 · FY2021 · CA · contact PI
Using Single Cell Analysis to identify therapeutic vulnerabilities in leptomeningeal melanoma metastases$224,460
R21 · FY2018 · CA · contact PI
Abrogation of Therapeutic Escape Pathways in BRAF Mutant Melanoma$232,736
P50 · FY2017 · CA · contact PI
Using Single Cell Analysis to identify therapeutic vulnerabilities in leptomeningeal melanoma metastases$187,050
R21 · FY2017 · CA · contact PI
Modeling and Targeting Adaptive Signaling Responses in Single NRAS Mutant Melanoma Cells$229,704
R21 · FY2016 · CA · contact PI
Abrogation of Therapeutic Escape Pathways in BRAF Mutant Melanoma$213,706
P50 · FY2016 · CA · contact PI
Microenvironment mediated drug resistance in melanoma.$346,525
R01 · FY2015 · CA · contact PI
Abrogation of Therapeutic Escape Pathways in BRAF Mutant Melanoma$211,354
P50 · FY2015 · CA · contact PI
Modeling and Targeting Adaptive Signaling Responses in Single NRAS Mutant Melanoma Cells$192,530
R21 · FY2015 · CA · contact PI
Microenvironment mediated drug resistance in melanoma.$336,129
R01 · FY2014 · CA · contact PI
Abrogation of Therapeutic Escape Pathways in BRAF Mutant Melanoma$220,387
P50 · FY2014 · CA · contact PI
Microenvironment mediated drug resistance in melanoma.$325,734
R01 · FY2013 · CA · contact PI
Abrogation of Therapeutic Escape Pathways in BRAF Mutant Melanoma$219,404
P50 · FY2013 · CA · contact PI
Microenvironment mediated drug resistance in melanoma.$346,525
R01 · FY2012 · CA · contact PI
Microenvironment mediated drug resistance in melanoma.$346,525
R01 · FY2011 · CA · contact PI